Skip to content
AIPressRoom

FundingHealthcare & Biotech

ALLOX Closes $10.5M to Expand Drug Discovery Platform

ALLOX raised $10.5M Seed led by Asabys to expand its AI-driven drug discovery platform and advance internal programs.

By Raina Gimmel

ALLOX raises $10.5M

The big picture: Biotechnology company ALLOX has raised $10.5 million in a seed funding round to expand its drug discovery platform and advance its internal development programmes. The round was led by Asabys through its Sabadell Asabys II fund, with participation from CDTI through SICC Innvierte and the Institut Català de Finances (ICF).

Why it matters:

  • Targeting the ‘undruggable’: ALLOX aims to overcome limitations in addressing challenging biological targets, such as protein-protein interactions and transcription factors, which have historically been difficult for conventional drug discovery approaches.
  • AI-driven insights: The company’s platform combines high-throughput genetics, experimental biology, and artificial intelligence to identify previously unexplored opportunities for developing small-molecule therapeutics.
  • Accelerating development: By integrating large-scale functional data with predictive AI, ALLOX seeks to unlock a broader range of challenging drug targets and accelerate the discovery of truly differentiated small-molecule drugs.

How it works:

  • Genetic mapping: The platform measures the effects of thousands of genetic mutations in parallel to map regions that influence protein folding and interactions.
  • Identifying binding pockets: This approach enables the identification of allosteric, orthosteric, and other regulatory sites, including potential binding pockets that could be used to develop targeted small-molecule drugs.
  • Data-driven predictions: The new funding will support the expansion of the platform’s capabilities and the development of proprietary AI models designed to predict therapeutic opportunities from large-scale biophysical datasets.

The catch: The drug discovery market is highly competitive, with numerous biotech and pharmaceutical companies investing heavily in AI-driven approaches. ALLOX will need to demonstrate clear differentiation and rapid progress in its internal pipeline to stand out amidst established players and other well-funded startups in a crowded field.

Key Facts

  • Company: ALLOX
  • Amount: $10.5M
  • Round: Seed
  • Investors: Asabys (lead), CDTI, Institut Català de Finances (ICF)
  • Founder: Júlia Domingo
  • Announced: 2026-10-29
  • Sector: AI-driven Drug Discovery
  • Headquarters: Barcelona, Spain

AIPressRoom Weekly

Every round we reported this week, the people behind the companies, and the events coming up. One email, every Tuesday.

More in Healthcare & Biotech

All